3D printed biodegradable multifunctional implants for effective breast cancer treatment

Luca, Matteo Di; Hoskins, Clare; Corduas, Francesca; Onchuru, Rachel; Oluwasanmi, Adeolu; Mariotti, Davide; Conti, Bice; Lamprou, Dimitrios A.

doi:10.1016/j.ijpharm.2022.122363

Cited by 11 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in order to avoid the deposition of too much material due to the increased nozzle diameter and to prevent poor printing quality caused by the increased printing pressure, the printing speed was set to 3.5 mm/s. [25] Under the light microscope, the PCL-CS-5-FU implant had a smooth surface with a certain level of light transmittance. Compared with the original implant form, photographs and light microscopy images demonstrated that the PCL-CS-5-FU implant did not show significant morphological differences after the drug release experiment.…”

Section: Discussionmentioning

confidence: 96%

“…In this study, a 3DP technology was used in order to formulate a sustained drug release implant loaded with 5-FU. The physicochemical characterisation of the PCL-CS-5-FU implant has been extensively tested in our previous study, [25] including differential scanning calorimetry, thermal gravimetric analysis, Fourier-transform infrared spectroscopy (FTIR), X-ray micro-computed tomography (µ-CT), X-ray diffraction (XRD) and mechanical behaviour. The PCL-CS-5-FU implant presents excellent thermal stability and good resistance to stretching, which guarantee the safety of the 3DP process at the printing temperature and provide sufficient stability to the host tissue.…”

Section: Discussionmentioning

confidence: 99%

“…The PCL-CS-5-FU implant presents excellent thermal stability and good resistance to stretching, which guarantee the safety of the 3DP process at the printing temperature and provide sufficient stability to the host tissue. [25] The advantages of the implant, such as high biocompatibility, slow degradable kinetics and suppression of fibroblast contractility, may therefore be useful as a therapeutic agent to prevent conjunctival fibrosis after glaucoma filtration surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Three 3D-printed implants (PCL-CS-5-FU, PCL-CS and PCL) were designed by Tinkercad and manufactured using the BIOX Bioprinter (CELLINK, Sweden) equipped with Thermoplastic Printhead. [25] The system integrates a Clean Chamber Technology, a dual high-powered fans channel air, and UV-C germicidal lights, allowing the removal of nearly 100% of unwanted particles and microorganisms to achieve a sterile implantable device. The implant containing only PCL was fabricated following the Cellink Printing Protocol.…”

Section: Manufacturing Of 3d-printed Implantsmentioning

confidence: 99%

See 3 more Smart Citations

3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma

Ioannou

Luo

Qin

et al. 2023

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

Objectives To develop a sustained release 5-fluorouracil (5-FU) implant by three-dimensional (3D) printing to effectively prevent conjunctival fibrosis after glaucoma surgery. Methods 3D-printed implants composed of polycaprolactone (PCL) and chitosan (CS) were fabricated by heat extrusion technology and loaded with 1% 5-FU. Light microscopy and scanning electron microscopy were used to study the surface morphology. The 5-FU concentration released over 8 weeks was measured by ultraviolet visible spectroscopy. The effects on cell viability, fibroblast contractility and the expression of key fibrotic genes were assessed in human conjunctival fibroblasts. Key findings The PCL–CS-5-FU implant sustainably released 5-FU over 8 weeks and the peak concentration was over 6.1 μg/ml during weeks 1 and 2. The implant had a smooth surface and its total weight decreased by 3.5% after 8 weeks. The PCL–CS–5-FU implant did not affect cell viability in conjunctival fibroblasts and sustainably suppressed fibroblast contractility and key fibrotic genes for 8 weeks. Conclusions The PCL–CS–5-FU implant was biocompatible and degradable with a significant effect in suppressing fibroblast contractility. The PCL–CS–5-FU implant could be used as a sustained release drug implant, replacing the need for repeated 5-FU injections in clinic, to prevent conjunctival fibrosis after glaucoma surgery.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Manufacturing Of 3d-printed Implantsmentioning

confidence: 99%

See 2 more Smart Citations

3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma

Ioannou

Luo

Qin

et al. 2023

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…AuNPs may act as radiation enhancers or local heat generators upon infrared irradiation, thus contributing to cancer cells’ death by local temperature enhancement. The PCL/AuNPs-PCL/CHT printed scaffold maintained a flexible structure suitable for the implant in the human body ( Figure 23 ), showed a good drug release profile and antibacterial activity due to the CHT properties, and long scaffold degradation time owing to the PCL component, useful for the drug release profile [ 299 ].…”

Section: Chitosan-based Inks For 3d Printing Applicationsmentioning

confidence: 99%

Chitosan-Based Biomaterials: Insights into Chemistry, Properties, Devices, and Their Biomedical Applications

et al. 2023

View full text Add to dashboard Cite

Chitosan is a marine-origin polysaccharide obtained from the deacetylation of chitin, the main component of crustaceans’ exoskeleton, and the second most abundant in nature. Although this biopolymer has received limited attention for several decades right after its discovery, since the new millennium chitosan has emerged owing to its physicochemical, structural and biological properties, multifunctionalities and applications in several sectors. This review aims at providing an overview of chitosan properties, chemical functionalization, and the innovative biomaterials obtained thereof. Firstly, the chemical functionalization of chitosan backbone in the amino and hydroxyl groups will be addressed. Then, the review will focus on the bottom-up strategies to process a wide array of chitosan-based biomaterials. In particular, the preparation of chitosan-based hydrogels, organic–inorganic hybrids, layer-by-layer assemblies, (bio)inks and their use in the biomedical field will be covered aiming to elucidate and inspire the community to keep on exploring the unique features and properties imparted by chitosan to develop advanced biomedical devices. Given the wide body of literature that has appeared in past years, this review is far from being exhaustive. Selected works in the last 10 years will be considered.

show abstract

Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment

Paleel,

Qin,

Tagalakis

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Timolol maleate (TML) is a beta-blocker drug that is commonly used to lower the intraocular pressure in glaucoma. This study focused on using a 3D printing (3DP) method for the manufacturing of an ocular, implantable, sustained-release drug delivery system (DDS). Polycaprolactone (PCL), and PCL with 5 or 10% TML implants were manufactured using a one-step 3DP process. Their physicochemical characteristics were analysed using light microscopy, scanning electronic microscopy (SEM), differential scanning calorimetry (DSC) / thermal gravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The in vitro drug release was evaluated by UV-spectrophotometry. Finally, the effect of the implants on cell viability in human trabecular meshwork cells was assessed. All the implants showed a smooth surface. Thermal analysis demonstrated that the implants remained thermally stable at the temperatures used for the printing, and FTIR studies showed that there were no significant interactions between PCL and TML. Both concentrations (5 & 10%) of TML achieved sustained release from the implants over the 8-week study period. All implants were non-cytotoxic to human trabecular cells. This study shows proof of concept that 3DP can be used to print biocompatible and personalised ocular implantable sustained-release DDSs for the treatment of glaucoma. Graphical Abstract

show abstract

3D printed biodegradable multifunctional implants for effective breast cancer treatment

Cited by 11 publications

References 30 publications

3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma

3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma

Chitosan-Based Biomaterials: Insights into Chemistry, Properties, Devices, and Their Biomedical Applications

Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment

Contact Info

Product

Resources

About